Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: HUTCHMED Announces NMPA Approval of Surufatinib investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
HutchMed (China) wins nod for HK listing ifre.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ifre.com Daily Mail and Mail on Sunday newspapers.
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
USA - English
Share this article
Share this article
SAN FRANCISCO and SUZHOU, China, June 6, 2021 /PRNewswire/ Innovent Biologics, Inc. ( Innovent , HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced with HUTCHMED (Nasdaq/AIM: HCM) that the results of the Phase 1b study in advanced colorectal cancer (CRC) patients were released today in an poster discussion at the 2021 American Association for Clinical Oncology (ASCO) Annual Meeting.
Middle East and Africa Neuroendocrine Tumors Market research report has set a bench-marking example for such a vibrant market that explores several recommendations and practical growth strategies in relation to the market. The chapter on the competitive landscape is presented well in the research report and is analy.